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Abstract 
Background: While in the past decades nucleic acid analysis has been predominantly carried out using quantitative 
low- and high-throughput approaches such as qRT-PCR and microarray technology, next-generation sequencing 
(NGS) with its single base resolution is now frequently applied in DNA and RNA testing. Especially for small non-
coding RNAs such as microRNAs there is a need for analysis and visualization tools that facilitate interpretation of the 
results also for clinicians.
Methods: We developed miFRame, which supports the analysis of human small RNA NGS data. Our tool carries out 
different data analyses for known as well as predicted novel mature microRNAs from known precursors and presents 
the results in a well interpretable manner. Analyses include among others expression analysis of precursors and 
mature miRNAs, detection of novel precursors and detection of potential iso-microRNAs. Aggregation of results from 
different users moreover allows for evaluation whether remarkable results, such as novel mature miRNAs, are indeed 
specific for the respective experimental set-up or are frequently detected across a broad range of experiments.
Results: We demonstrate the capabilities of miFRame, which is freely available at http://www.ccb.uni-saarland.de/
miframe on two studies, circulating biomarker screening for Multiple Sclerosis (cohort includes clinically isolated syn-
drome, relapse remitting MS, matched controls) as well as Alzheimer Disease (cohort includes Alzheimer Disease, Mild 
Cognitive Impairment, matched controls). Here, our tool allowed for an improved biomarker discovery by identifying 
likely false positive marker candidates.
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Background
During the past three decades, molecular analysis of 
DNA and RNA became more and more important. In 
the 1990’s, the low-throughput technologies such as 
Western Blot and quantitative polymerase chain reac-
tion have been augmented by high-throughput technolo-
gies, namely microarrays. While microarrays allowed for 
profiling of thousands of molecules in parallel, producing 
orders of magnitude more data, qRT-PCR still remained 
gold standard. All these technologies are thought for 
quantitative analysis of molecular markers. Around one 
decade ago, next-generation sequencing (NGS) became 
available. With its single base resolution, NGS outper-
formed microarrays by several orders of magnitude con-
sidering the information content. This incredible flood 
of data requires sophisticated computational approaches 
for quantitative but also qualitative analysis of NGS data. 
Especially for DNA and mRNA a magnitude of analy-
sis and visualization toolkits, web based as well as stand 
alone, are available. For miRNAs, that are known to be 
key regulators and valuable biomarker candidates for 
various human pathologies, respective tools are currently 
still under development.
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One key challenge in small RNA sequencing analysis is 
the detection of so far unknown molecules. To address 
this topic, several tools have been developed. A promi-
nent example is miRExpress, a stand-alone application 
for detecting known miRNAs along with novel miRNA 
candidates [1]. Another example, miRanalyzer is avail-
able as a stand-alone solution, however it offers also the 
option to carry out the analyses online in a web based 
version [2, 3]. Besides the detection of novel miRNAs, 
miRanalyzer identifies differentially expressed miRNAs 
and predicts miRNA targets. Likewise as stand-alone 
and web service, SeqBuster allows for detection of vari-
ants of miRNAs for known markers and can moreover be 
applied to discover dys-regulated miRNAs and the pre-
diction of targets [4].
Besides these tools specialized algorithms such as mir-
Tools [5, 6], DARIO [7], WapRNA [8], eRNA [9] or E-miR 
[10] have been proposed. Among the most widely applied 
miRNA NGS tools is miRDeep/miRDeep2, allowing 
for the prediction of novel miRNAs [11, 12]. Respective 
tools are now stitched together in pipelines. An example 
of a comprehensive set of analysis tools is CPSS, includ-
ing analysis of length distribution and genome mapping, 
quantification, prediction of novel miRNAs, identifica-
tion of differentially expressed miRNAs, and functional 
enrichment, e.g. of GO terms [13]. A second example is 
omiRas, detecting dys-regulated miRNAs and revealing 
insights into molecular mechanisms by annotation, com-
parison and visualization of interaction networks of ncR-
NAs [14].
While the above mentioned tools that represent just 
a selection of available NGS analysis solutions, focus on 
prediction of miRNAs and complex analyses to put miR-
NAs into a larger context, solutions that specifically ana-
lyze and visualize reads across the precursor molecules 
of specific biomarkers are not common. One example 
towards this direction is MISIS, a tool to visualize and 
analyze maps of small RNAs derived from viruses [15]. 
MISIS displays RNA reads as histogram along a given ref-
erence sequence.
However, especially for small non-coding RNAs the 
visual inspection of reads across the precursor can sup-
port the discovery of potentially false positive biomarker 
candidates, to select the right candidates for further 
experiments and to interpret the results of the high-
throughput experiments. We developed miFRame, a 
tool for the analysis of single miRNAs as well as miRNA 
sets from human NGS data that can be easily applied by 
researchers. Comparable to other tools, miFRame per-
forms quantification of expression on miRNA precursors 
and mature forms of miRNAs, and allows for discovering 
differentially expressed markers. Besides this functional-
ity, miFRame however also offers to discover potentially 
dys-regulated novel mature miRNAs, differentially 
regulated iso-miRNAs and performs a per-base expres-
sion analysis. Moreover, miFRame offers an aggregation 
analysis. Here, results of one user are compared to other 
users’ results, e.g., to provide evidence whether a novel 
miRNA isoform is actually specific for an experiment or 
frequently detected in other NGS analyses. If this is the 
case, an NGS artifact may be more likely than an actual 
finding, allowing for improved priorization of replica-
tion/validation experiments. Among the most important 
features of miFRame besides easy data input and sophis-
ticated analyses along miRNA precursors is a concise 
representation of results: for each miRNA separately, key 
findings are represented in various manners, enabling 
users to inspect the most important markers visually.
Methods
miFRame
miFRame is a freely available web-service for analyz-
ing miRNA NGS data (http://www.ccb.uni-saarland.de/
miframe/). The front-end is implemented in PHP and 
substantial parts of secondary miRNA analysis are car-
ried out using proprietary R and Python scripts. No addi-
tional packages beyond the core packages in R version 
3.0.2 were used. The analyses implemented in miFRame 
are described in the Results section of the manuscript. 
miFrame relies on the miRBase (http://www.mirbase.
org/), one of the most frequently used miRNA reposi-
tories. From the miRBase, the hsa.gff file containing the 
genomic coordinates for all human miRNAs and the 
mature.fa file containing all mature miRNA sequences 
(for all organisms) are used. Currently, miFRame is 
restricted to human data, thus all non-human miRNAs 
are filtered out of the analysis. A detailed step-by-step 
tutorial is available from the web resource.
Data sets
To demonstrate the functionality of miFRame, we 
applied our tool to two data sets on Multiple Sclerosis 
and Alzheimer consisting of a total of 133 samples [16, 
17]. In brief, the following cohorts were included: Alz-
heimer Disease (AD) patients (n =  54), Mild Cognitive 
Impairment (MCI) patients (n = 20), Alzheimer control 
set (n =  22), Multiple Sclerosis patients (n =  15), Mul-
tiple Sclerosis control set (n  =  22). All samples were 
sequenced on Illumina HiSeq systems. As source, whole 
blood has been used. Details on library preparation and 
sequencing are presented in [16, 17]. The data that have 
been used for this analysis are available for download 
from the web resource. Beyond the standard parameters 
we also tested the influence of different parameter sets 
on the results, specifically the influence of the window 
sizes is described in detail in the Results section. The 
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pre-calculated examples (Alzheimer and MS) are avail-
able from the miFRame homepage without password 
protection.
Results
We developed miFRame, a tool for the analysis and vis-
ualization of human miRNA NGS data. miFRame is a 
web-service developed with the intention to be used by 
life scientists and clinicians. In this section we will first 
explain the different input methods for our tool, the avail-
able analyses and tested hypothesis and the output. The 
full workflow is presented in Figure 1. Then we demon-
strate the capabilities of miFRame on two NGS data sets. 
Specifically, the program has been applied in order to 
investigate miRNAs in Alzheimer and Multiple Sclerosis 
patients. To this end we collected NGS data from Mul-
tiple Sclerosis (MS) patients and respective controls as 
well as Alzheimer Disease (AD), Mild Cognitive Impair-
ment patients (MCI) and a respective control set. The 
NGS data have been previously published (see “Methods” 
section). Altogether, 133 individuals have been included 
in the analysis and 1,319 miRNAs have been discovered 
in at least a single sample. Since different NGS runs can 
yield substantially varying total read counts, all data have 
been normalized to one million reads (reads per million, 
RPM).
Figure 1 miFRame workflow. The figure sketches the three-layered workflow of miFRame. First, NGS data have to be uploaded along with a param-
eter set, next statistical analyses are carried out and finally, results are presented to the user.
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Data input
miFRame gets pre-processed NGS data along with a 
parameter set as input. The parameter input can be eas-
ily performed via the web-interface and the following 
three input options are supported. First, our tool offers 
to re-enter a previous study ID to access analysis results 
that have been performed earlier. In that, miFRame also 
allows for sharing analysis results with collaborators. 
Besides the unique study ID users also get a password 
to protect their data. With that ID and the password, 
collaboration partners can directly access the analysis 
results (option 1). Second, arf files that are the standard 
output of miRDeep2, a popular miRNA analysis tool, 
can be uploaded (option 2). Besides the arf files, the user 
has to provide a file containing the total number of reads 
per sample that should be used for normalization. Here, 
the total reads from the NGS run directly can be used, 
or alternatively, the read counts after matching to the 
genome of H. sapiens or no normalization can be per-
formed. As third input set, the grouping of the arf file to 
classes has to be uploaded as tab delimited data file (file 
name and class for each sample in an own row). Exam-
ple input is provided for all three files on the miFrame 
homepage. Third, it is possible to use any other miRNA 
annotation tool and to generate the annotation files for 
upload with miFRame (option 3). The latter option allows 
for largest flexibility and transfer of small data sets in the 
range of few megabytes but substantial local pre-pro-
cessing by the user is required. A more detailed descrip-
tion of the different input formats is available on the 
miFRame main webpage (http://www.ccb.uni-saarland.
de/miframe/).
As parameters the user can specify significance thresh-
old, select whether just single positions or many bases 
across the precursor have to be significantly changed (to 
observe differential regulation of one mature miRNA, 
around 15 positions should at least be significant), a 
window size for detection of iso-microRNAs (typical 
parameters are 2–4 bases) and the different analyses to 
be carried out. Moreover, the user can specify the sta-
tistical test to be applied (parametric t test for normally 
distributed data or Wilcoxon Mann–Whitney test) and 
the graphics output format (pdf vector graphics, jpeg or 
png). Finally, the user can decide whether the data should 
be used for the aggregation analysis. In this case he gets 
the number of significant results others obtained for the 
respective miRNAs and his own data are added to the 
data pool.
Analysis
Expression analysis
Here, miFRame tests the hypothesis that all reads map-
ping to the precursor are differentially expressed between 
a case and control cohort. The mean read count per sam-
ple across the precursor is calculated. By applying the 
hypothesis test specified by the user, average count in 
case and control cohort is compared to each other and a 
p-value per miRNA precursor is calculated.
Mature expression analysis
In this step, miFRame tests the hypothesis that miRNA 
precursors are differentially expressed between cases and 
controls. To this end, the average read count per sam-
ple on each mature 3′ and 5′ miRNA is calculated and 
by applying the hypothesis test specified by the user, a 
p-value is calculated.
3′ to 5′ expression analysis ratio
Here, miFRame searches for miRNAs that show either 
opposite or same differential expression between cases 
and controls on the 3′ compared to the 5′ mature forms 
of miRNAs. First, miRNAs with just a single mature form 
are omitted, first. Then, for each remaining miRNA the 
fold changes and p-values for the 3′ and 5′ forms are 
determined analogously to the mature expression analy-
sis. From these two fold changes, the difference between 
the 3′ and the 5′ mature form is calculated. miRNA pre-
cursors with resulting expression quotients close to 1 
show the same up- or down-regulation of both mature 
forms, while those miRNAs with fold changes ≫1 are 
more up-regulated in the 5′ mature form and miRNAs 
with fold changes ≪1 are more up-regulated in the 3′ 
mature form.
Per‑base expression analysis
In this analysis, miFRame checks how many base posi-
tions across the precursor of each miRNA are signifi-
cantly differentially expressed in cases compared to 
controls. Most computational approaches just consider 
either maximal or average expression across the mature 
forms of miRNAs. In several cases, however, just few 
positions, especially at the 3′ or the 5′ end of the mature 
miRNA(s) are significantly different between two cohorts. 
These sites are detected by the per-base expression analy-
sis but are usually not discovered by considering the full 
precursor or mature miRNAs (see also window analysis).
Novel mature miRNA analysis
For a substantial amount of miRNAs in the miRBase 
just a single mature form (either the 3′ or 5′) is known. 
However, in many cases a significant number of reads 
maps exactly to positions matching the respective second 
mature form (5′ or 3′) of known miRNAs. To this end, 
miFRame calculates for those miRNAs where just a single 
mature form is known whether reads are matching to the 
respective 3′ or 5′ mature form. Additionally, miFRame 
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calculates whether the respective mature form shows 
significantly different expression in cases as compared to 
controls and outputs how many reads are located on this 
potential novel mature miRNA.
Window analysis
As described in the per base analysis section, it is often 
the case that only a few single positions, predominantly 
at the 3′ or 5′ end of the mature miRNA(s) belonging to 
one precursor are significantly changed or show at least 
a lower p-value value than the remaining part of the pre-
cursor or mature form(s) of the miRNA. These sites are 
frequently not taken into account in statistical analyses or 
are down-weighted by averaging across the mature miR-
NAs. miFRame allows the user to select a window size in 
the parameter selection step. Then, it calculates the per-
centage of bases covered in this window with respect to 
the 3′ and 5′ end of the 3′ and 5′ mature miRNA form. In 
consequence, for each precursor with two mature forms 
4 percentages in cases and controls are calculated along 
with the difference between the two cohorts while for 
precursors with just one mature form only two percent-
ages are calculated. Additionally, miFRame also outputs 
the respective motifs at the 3′ and 5′ end of the mature 
miRNAs. Thus, mature miRNAs with isoforms in specific 
traits can be well detected.
Aggregation analysis
In case the user decided to carry out the aggregation 
analysis, just the relevant findings from the current study 
are stored anonymously in a local database. In return, 
the relevant findings from that user are compared to the 
database such that it becomes clear whether e.g. a novel 
mature miRNA is specific for a certain trait or is reported 
in many experiments, making a false positive finding by 
NGS artifacts more likely. This analysis may help to pri-
oritize the replication and validation experiments by 
selecting findings that are less frequently discovered.
Output of results
One key criterion for miFRame was the concise graphi-
cal representation of results such that the high through-
put data can be explored in great detail by researchers 
in order to detect potential false positive mappings. Our 
tool offers three different output categories. First, all rel-
evant results per analysis are shown as Manhattan plots. 
These plots, well known from genome wide association 
studies (GWAS) show the negative decade logarithm of 
p-values as function of the genomic position, allowing for 
detection of hot spots in the genome immediately. Two 
examples for such Manhattan plots, representing the 
results of the expression analysis for Alzheimer versus 
matched controls and Multiple Sclerosis patients versus 
matched controls, are presented in Figure 2.
As second output, miFRame presents detailed results 
for all analyses that lead to significant findings. The 
result tables consist of two parts, the left hand con-
tains key characteristics such as read counts, p-values, 
fold changes, etc. All entries can be sorted in increas-
ing or decreasing manner for the respective features. 
The right hand part of the result tables consists of three 
thumbnails for each miRNA. Clicking each of them 
Figure 2 Manhattan plots. The results of the expression analysis for MS and AD are presented. Each microRNA included in the set is located on 
the genome (x-axis) and for this miRNA the negative decade logarithm is presented on the y-axis. The higher the respective data points, the more 
significant the results are. The graphic reveals that the AD study showed increased significance as compared to the MS study (scale on the y-axis).
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opens high-resolution graphical representations of the 
respective results. The three representations include the 
following plot: (1) significant bases across the precur-
sor molecules. For each miRNA, the negative decade 
logarithm of p-values is presented. Remarkably, for each 
base of the precursor an own bar is drawn. Green bars 
represent down-regulation in cases while red bars mean 
up-regulation in cases as compared to controls. (2) read 
distribution across the precursor. Each sample is pre-
sented as line plot along the miRNA precursors. Here, 
red lines correspond to cases while green lines corre-
spond to controls. (3) Pileup plots for each miRNA are 
also calculated. These plots show in the middle the pre-
cursor miRNA sequence. Mature forms are colored in 
blue and red, respectively, and the area where reads map 
to known miRNAs is shaded in blue. Above the precursor 
sequence, the consensus sequence per case individual is 
presented while below the precursor sequence the con-
sensus per control individual is drawn. Interpreting these 
results allows for easy detection of miRNAs that show 
inaccurate mappings, indicating potentially false positive 
findings, or for discovering iso-miRNAs. In case the user 
decided to carry out the aggregation analysis, a fourth 
plot is generated, showing in how many different experi-
ments the respective miRNA has been included and in 
how many of these experiments a significant finding was 
calculated.
Besides the web-based representation of the results all 
findings can be downloaded as compressed folder. The 
download does not include just the Manhattan plots, bar 
diagrams, read distribution graphics and pileup plots but 
also tab delimited flat files that can be imported in vari-
ous standard software for spreadsheet analysis.
Application of miFRame to Alzheimer and multiple 
sclerosis
To demonstrate the usability of miFRame we applied the 
tool to two publicly available data sets that can be also 
downloaded from the miFrame homepage, containing 
circulating miRNA profiles from whole blood of Alzhei-
mer and Multiple Sclerosis patients [16, 17]. The data sets 
are sketched in the “Methods” section. Detailed descrip-
tion can be found in the respective original publications. 
For both data sets the full analysis has been carried out 
using the standard parameters of miFRame and analysis 
results are available from the miFRame homepage (refer-
ence ID and password are provided in the “Methods” sec-
tion). All analyses have been carried out on samples with 
read counts normalized to one million total reads.
Expression analysis
In Figure  2, Manhattan plots for the expression analy-
sis of both data sets are presented. The Alzheimer panel 
on top of the figure reveals substantially more dys-reg-
ulated miRNAs on chromosome 1 and 2 (left part) as 
compared to the Multiple Sclerosis data set on bottom 
of the figure. Vice versa, the Multiple Sclerosis data set 
shows a tendency for clustering of dys-regulated miR-
NAs on the smaller chromosomes (right part of the fig-
ure). Altogether, the Alzheimer data set shows much 
lower p-values and thus by far more significantly dys-
regulated miRNAs. The most significant dys-regulation 
in case of Alzheimer was calculated for hsa-miR-1468-5p 
(p = 9 × 10−9) while the most significant miRNA in case 
of Multiple Sclerosis was hsa-miR-3179 (p  =  0.001). In 
both cases the visual inspection of the mapping results 
did not reveal critical read alignments but the NGS reads 
mapped well to the known mature miRNAs. Another 
miRNA, which was significant in Alzheimer Disease, was 
hsa-miR-3150a-3p (p = 6 × 10−5, not significant in Mul-
tiple Sclerosis). Here, the pileup plots, however, showed a 
substantial number of reads mapping outside the actual 
mature form of the miRNA in Alzheimer and Multiple 
Sclerosis patients as well as matched controls (Alzhei-
mer vs. controls: Figure  3a, Multiple Sclerosis vs. con-
trols Figure  3b). Since, driven by the larger cohort size, 
the Alzheimer panel showed more significant results as 
compared to the Multiple Sclerosis NGS study, we focus 
in the following on Alzheimer Disease.
As next step following the expression analysis we spe-
cifically searched for miRNAs where both mature forms 
show significant dys-regulation. Indeed we detected 
several miRNAs with up-regulation of the 3′ form and 
down-regulation of the 5′ mature miRNA or the opposite 
behavior. Remarkably, miR-3180 showed up-regulation 
of miR-3180-3p (p = 0.007) while miR-3180-5p was sig-
nificantly down-regulated (p =  0.003). Here, the degree 
of differential expression between the 3′ and the 5′ form 
was 7-fold. Vice versa, miR-202 showed down-regulation 
of miR-202-3p (p = 0.05) while miR-202-5p was signifi-
cantly up-regulated (p = 0.04). In this case, the degree of 
differential expression between the 5′ and the 3′ form was 
again sevenfold. Pileup plots for both miRNAs showing 
the accurate mapping pattern of reads to the mature miR-
NAs are presented in Figure 4 (a: miR-3180, b: miR-202).
While these analyses generally could have been done 
using qRT-PCR or microarray data, the NGS data how-
ever offer the additional avenue of a detailed per base 
data analysis.
Analysis of mapped reads
First, we investigated whether we find reads mapping to 
precursors where just the 3′ or the 5′ mature miRNA has 
been annotated in miRBase 20, whether the respective 
reads are mapping to the potential novel mature miRNA 
in an adequate manner and whether the respective 
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potential novel mature miRNA is dys-regulated between 
Alzheimer Disease patients and matched controls. 
Indeed, we found several miRNAs matching the criteria 
above. One of the most prominent examples was miR-
2110. Here, we found a potential novel mature form con-
sisting of 26 bases. On average, 52 reads mapped to this 
novel mature form, more interestingly, expression for 
Alzheimer Disease patients was 1.6 fold higher than for 
controls (p = 0.0001). The graphical output generated by 
miFrame for this miRNA is presented in Figure 5a (upper 
part: pileup plot, lower right part: along precursor read 
distribution, lower left part: along precursor p-values). 
While this mature form has not been annotated in the 
miRBase, yet, a recent publication described the respec-
tive miRNA as novel mature 3′ form of miR-2110 [18]. In 
this case, the aggregation analysis highlighted that in so 
far 100% of all analyses (time of analysis: June 2015) car-
ried out whit the aggregation option enabled this novel 
mature miRNA was observed. In some cases, we observe 
miRNAs in a position of a precursor where no mature 
form is expected at all while the actual mature form as 
observed in the miRBase is not covered by a single read. 
One respective example, miR-4472-2 is presented in Fig-
ure 5b. Again, reads outside of the annotated 5′ mature 
miRNA were observed in 100% of all analyses carried 
out.
Figure 3 Pileup plot for miR-3150a-3p. The figure presents an extract of pileup plots for hsa-miR-3150a-3p in the two studies (a AD; b MS). Samples 
on top represent cases and on bottom controls. Each sample where at least a single read mapped to the precursor get an own line. The sequence 
in the middle corresponds to the precursor sequence, the mature miRNA (in this case the 3p mature form) is colored in red. The blue shaded area 
marks the mature part of this miRNA. In both cases, AD and MS, reads are partially mapping outside the mature form of this miRNA.
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Besides detecting novel mature miRNAs, miFRame also 
offers to discover iso-miRNAs. Here, specifically variants 
with extended mature miRNA reads in a window specified 
by the user are reported. To quantify the effect, miFRame 
calculates the frequency of reads mapping for samples in 
the window outside the annotated miRNA. Besides the 
tabular output, again, the respective graphical output sup-
ports to detect potential iso-microRNA candidates. These 
are shown by peaks in the significance plots at the 3′ and/
or 5′ end of known mature miRNAs. A representative 
example is presented in Figure  6. Here, the significance 
and read distribution across the precursor for miR-30d 
is presented. For the 5′ mature form of this miRNA, sig-
nificantly extended reads in case of Alzheimer Disease 
patients can be detected. While the average significance is 
in the range of 2 × 10−4, p-values for the 3′ and 5′ end of 
the mature miRNA are as high as 10−6. Other interesting 
examples are shown in Figure 7. Figure 7a represents the 
pileup plot for miR-1307-5p. Here, control samples show 
in 64% of cases an extension by 1 or 2 bases at the 3′ side of 
the 5′ mature miRNA. In contrast, just 29% of Alzheimer 
Disease patients show such an extension by 1 or 2 bases. 
The aggregation analysis showed that respective differ-
ences are observed in around one-third of all analyses (pie 
plot in the lower part of that figure). Figure 7b presents the 
pileup for miR-3127-3p. In this case, Alzheimer Disease 
patients show a doubled frequency of bases covered to the 
3′ end of this miRNA as compared to controls. Here, the 
aggregation analysis revealed that respective changes are 
usually not observed. Finally, Figure 7c presents miR-378b. 
The 3′ end of the 3′ miRNA is covered in 50% of all cases at 
a window size of 2 while this holds just for 5% of controls. 
Again, just very few results had similar reads mapping at 
the 3′ end of this miRNA.
Figure 4 Expression ratio of 3p and 5p mature forms. In this figure, opposite fold changes of the 3p and the 5p mature form of miRNAs is shown 
for two miRNAs, miR-3180 in panel a and miR-202 in panel b. The right part shows the pileup plots, the sequence in the middle represents the pre-
cursor, the two mature forms are highlighted in red (5p) and blue (3p) and with the blue shaded area. The right hand side shows the negative decade 
logarithm of the p-value for each single position. Up-regulated positions on the precursor in controls are colored in green and red bars correspond 
tow don-regulated positions on the precursor. The two red and green blocks correspond to the two mature forms, respectively. Clearly, the 3p form 
is up-regulated while the 5p form is down regulated for miR-3180 (panel a) while miR-202 shows the opposite behavior (panel b).
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Figure 5 a Potential novel mature miRNA. The upper part of the figure presents the pileup plot (similar to Figures 3, 4). Just one mature form is 
annotated in miRBase V20, namely the 5p form (colored in red and shaded in blue). Nevertheless, many reads map to the position where a 3p version 
could be located. The lower right part shows the significant down-regulation of this miRNA in controls as compared to Alzheimer Disease patients. 
The lower left image presents beyond the significance the absolute rad count per sample. Green samples correspond to cases and red samples to 
controls. b For miR-4472, just one mature form (5p) is annotated in the miRBase. While we do not observe mappings to this position, we observe 
mappings to the position where the 3p mature form could be expected.
Figure 6 potential isoforms of miR-30d-5p. The bar-plot on the right hand side shows increased significance at the edges of miR-30d-5p. In this 
case, Alzheimer Disease patients have higher expression on few base positions outside the annotated miRNA. This can be also seen on the read 
distribution plot on the right hand side. At position 26–29, Alzheimer Disease patients (green) have significantly higher coverage than controls.
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Influence of the window size
Especially the parameter of the window size potentially 
has a substantial influence of the results of miFRame. We 
thus explored how divergent results are with respect to 
different window sizes ranging from 1 to 4. Thereby we 
observed a generally high stability of results independ-
ent of the window size. For the three before mentioned 
miRNAs, the results are presented in Table 1. miR-1307 
has with 1-base window values of 31.5% (AD) and 68.1% 
(control) with a fold change of 0.46. For 2-base windows 
values shift to 28.7 and 63.6% (fold change of 0.45). For 
3-base windows values are 20.4 and 45.5% (fold change of 
0.45) and for 4-base windows 15.7 and 34.4%. Although 
the percentages in AD and control substantially decrease 
from 1 to 4 bases, the ratio stays constant. The same 
holds also for the other miRNAs in Table 1.
Discussion
As described in the Introduction, analysis tools for next 
generation sequencing data of small non-coding RNAs 
are constantly improved and novel tools are imple-
mented. While a substantial portion of these tools 
Figure 7 a Pileup plot for miR-1307. In case of miR-1307-5p, control patients show increased frequency of 1–2 base shifts at the 3p end. The pie 
diagram at the lower part of the figure shows that around one-third of all analyses revealed respective iso-forms. b Pileup plot for miR-3172. For miR-
3127-3p, AD samples are frequently shifted by 1–2 bases to the 3p end of this miRNA. The pie chart as result of the aggregation analysis indicates 
that respective results are usually not observed. c Pileup plot for miR-378b. Extended mappings at the 3p end of this miRNA are almost exclusively 
observed for AD patients.
Page 11 of 12Backes et al. J Transl Med  (2015) 13:224 
focuses on the detection of novel miRNAs from NGS 
reads, other tools aim at improved understanding of 
pathogenic processes by integrating miRNA data to bio-
chemical pathways and linking them with target genes.
Besides furthering our understanding of human patho-
genic processes, miRNAs however offer themselves as 
biomarkers to detect disease in time or monitor disease 
progression. With miFRame, we developed a tool that 
supports the investigation and graphical analysis of bio-
marker candidates. Besides classical quantitative analy-
ses, miFRame also provides qualitative analyses such as 
the detection of novel mature forms of miRNAs or the 
discovery of potential iso-miRNAs, specifically extended 
mature forms of miRNAs.
Key functionality of miFRame is the concise graphi-
cal representation of the high-throughput data. For each 
analysis, an overview plot showing the significant results 
along the genome is generated, a well-known represen-
tation from Genome Wide Association Studies. More 
importantly, three plots are generated for each miRNA, 
showing the significance and respectively read distribu-
tion along the miRNA precursor together with pileup 
plots, representing the consensus sequence of all reads 
and all samples mapping to this precursor.
The potential of miFRame is presented on Multi-
ple Sclerosis and Alzheimer Disease whole blood NGS 
data. Beyond the known markers for this disease, espe-
cially in case of Alzheimer novel markers were identi-
fied. The increased significance in AD compared to MS 
may be partially due to the larger cohort size for the AD 
study. Beyond discovering of differentially regulated 
miRNAs, our analysis also revealed miRNAs with dif-
ferent fold changes on the 3′ to 5′ form in AD as com-
pared to controls, novel potential mature forms of known 
miRNAs as well as potential isoforms. Remarkably, in 
case of the Alzheimer data set, we originally reported 
a 12-miRNA signature that has been fully validated by 
qRT-PCR. While in 10 cases results matched well, for 2 
miRNAs, however, the qRT-PCR data did not correspond 
to the NGS results (miR-26a-5p and miR-1285-5p). For 
miR-26a-5p, miFRame did not reveal a potential source 
leading to a false positive biomarker. In contrast, for 
miR-1285, miFRame revealed a wired read mapping 
to the mature 5′ form on the precursor. The results are 
shown in detail in Additional file 1: Figure S1. Only few 
bases at the 5′ end of the miRNA were highly significant, 
the difference between Alzheimer Patients and controls 
decreased towards the middle of that miRNA and many 
reads mapped outside the actual annotated mature 5′ 
biomarker, representing a potential mapping issue in case 
of this biomarker, which may lead to a divergent qRT-
PCR result.
Conclusion
We developed miFRame, a tool that gets miRNA NGS 
data and carries out statistical analysis of read counts as 
well as detection of novel mature miRNAs and iso-miR 
analysis. Compared to other tools, miFRame has multi-
ple additional features, for example users can share their 
aggregated and anonymized results and as benefit get the 
feedback how many other researchers observed similar 
results, highlighting potential systematic errors and help 
to prioritize candidates for validation studies. The very 
detailed graphical representation of the results allows 
researchers to interpret and evaluate relevant findings 
from their experiments. Thus, our tool augments cur-
rent miRNA NGS analysis pipelines that are tailored for 
the detection of novel miRNAs, the prediction of target 
genes or functional miRNA enrichment analysis.
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 AD 31.5 28.7 20.4 15.7
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 Quotient 0.46 0.45 0.45 0.46
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miR-3127
 AD 82.7 48.1 32.1 24
 Control 50 25 16.7 12.5
 Quotient 0.6 0.52 0.52 0.52
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